Participants 50 118 4
hyperglycemic patients with non-ST elevation acute coronary syndrome
Participants 285 349 6
patients with diabetes receiving standard treatment for diabetes
Participants 691 761 5
patients with diabetes and A1C of >or=8-10% at randomization (n = 171)
Participants 862 888 3
placebo-adjusted (n = 182)
Participants 968 1040 3
patients with FPG of 150-400 mg/dl at randomization, ranolazine (n = 131
Participants 1056 1072 3
placebo (n = 147
Participants 1709 1776 3
patients with cardiovascular disease and poorly controlled diabetes
